Risk Stratification for Arrhythmic Sudden Cardiac Death: Identifying the Roadblocks

Athough it is difficult to determine the precise number, the range for the number of sudden cardiac deaths (SCDs) per year in the United States alone has been reported from 184 000 to 462 000,1 with estimates that 50% to 70% are due to tachyarrhythmic mechanisms. Regardless of where within this range the true number lies, this represents a large epidemiological problem that warrants serious attention and attempts to identify solutions. There are many obstacles to achieving this laudable goal. First and foremost, although the vast majority of SCD victims have underlying structural heart disease (in particular, coronary artery disease), a significant percentage of SCD victims have previously unrecognized cardiac disease2; on autopsy, advanced coronary artery disease with or without evidence of unstable plaques and acute or healed myocardial infarctions (often clinically silent) are commonly detected.2,3 The American Heart Association estimates that 195 000 first silent myocardial infarctions occur per year.4 Strategies to reduce SCD among individuals without known cardiac disease must therefore focus on better screening and identification of risk factors for coronary disease, with either known risk factors or heretofore unknown or unidentified risk factors. In patients with known cardiac disease, there may be diverse pathogeneses for sudden death, including primary ventricular tachyarrhythmias and acute myocardial ischemia/infarction, among others. Although therapies exist for treatment of life-threatening ventricular tachyarrhythmias and prevention of myocardial infarction/coronary artery plaque rupture, significant challenges exist in identifying the individual patient within population subgroups who is at substantial personal risk of these events, and in whom the most intensive therapies could and should be applied. Although the incidence of out-of-hospital cardiac arrest due to ventricular tachycardia/fibrillation appears to be declining over time,4 this pathogenesis for SCD still occurs commonly. This article will therefore focus on the challenges and roadblocks …

[1]  D. Lloyd‐Jones,et al.  Risk Prediction in Cardiovascular Medicine Cardiovascular Risk Prediction Basic Concepts, Current Status, and Future Directions , 2010 .

[2]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[3]  H. Huikuri,et al.  Attenuated recovery of heart rate turbulence early after myocardial infarction identifies patients at high risk for fatal or near-fatal arrhythmic events. , 2010, Heart rhythm.

[4]  Fred S Apple,et al.  Etiology of sudden death in the community: results of anatomical, metabolic, and genetic evaluation. , 2010, American heart journal.

[5]  D. Mozaffarian,et al.  Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population , 2009, Circulation.

[6]  A. Castellanos,et al.  Indications for implantable cardioverter-defibrillators based on evidence and judgment. , 2009, Journal of the American College of Cardiology.

[7]  A. Moss,et al.  Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators. , 2009, Heart rhythm.

[8]  J. Goldberger Evidence-based analysis of risk factors for sudden cardiac death. , 2009, Heart rhythm.

[9]  J. Hartikainen,et al.  Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction† , 2008, European heart journal.

[10]  Robert J. Myerburg,et al.  Implantable cardioverter-defibrillators after myocardial infarction. , 2008, The New England journal of medicine.

[11]  Barry J Maron,et al.  American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardi , 2008, Journal of the American College of Cardiology.

[12]  M. Josephson,et al.  A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. , 2008, Journal of the American College of Cardiology.

[13]  T. Young,et al.  Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Coun , 2008, Circulation.

[14]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[15]  A. Moss,et al.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. , 2008, Journal of the American College of Cardiology.

[16]  Robert S Sheldon,et al.  Noninvasive risk assessment early after a myocardial infarction the REFINE study. , 2007, Journal of the American College of Cardiology.

[17]  Michael R Gold,et al.  Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. , 2007, Journal of the American College of Cardiology.

[18]  N. Cook Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[19]  Philip Greenland,et al.  Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry). , 2007, The American journal of cardiology.

[20]  E. Loveman,et al.  Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: A systematic review and economic evaluation , 2007, International Journal of Technology Assessment in Health Care.

[21]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[22]  A. Tsiatis,et al.  Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.

[23]  Lu Tian,et al.  Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease , 2006, Annals of Internal Medicine.

[24]  Alvin I Mushlin,et al.  The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. , 2006, Journal of the American College of Cardiology.

[25]  Rebecca T. Cover,et al.  Patients’ Perceptions of Cholesterol, Cardiovascular Disease Risk, and Risk Communication Strategies , 2006, The Annals of Family Medicine.

[26]  Karen L. Gunson,et al.  Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. , 2006, Journal of the American College of Cardiology.

[27]  Christos Savopoulos,et al.  Circadian Rhythm in Sudden Cardiac Death: A Retrospective Study of 2,665 Cases , 2006, Angiology.

[28]  A. Waldo Sudden Death in Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or BothSolomon SD, for the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators (Brigham and Women's Hosp, Boston; et al) N Engl J Med 352:2581-2588, 2005§ , 2006 .

[29]  V. Fuster,et al.  Primary prophylaxis with the implantable cardioverter-defibrillator: The need for improved risk stratification , 2005 .

[30]  S. Solomon,et al.  Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. , 2005, The New England journal of medicine.

[31]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[32]  Michael R Gold,et al.  Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. , 2004, Heart rhythm.

[33]  A. Khasnis,et al.  Prophylactic Defibrillator Implantation in Patients With Nonischemic Dilated Cardiomyopathy , 2004 .

[34]  A. Kadish,et al.  Impact of Nontraditional Antiarrhythmic Drugs on Sudden Cardiac Death , 2004 .

[35]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[36]  M. Pepe,et al.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. , 2004, American journal of epidemiology.

[37]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[38]  J J Bailey,et al.  Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. , 2001, Journal of the American College of Cardiology.

[39]  S. Willich,et al.  Cold Monday mornings prove dangerous: epidemiology of sudden cardiac death , 2001, Current opinion in critical care.

[40]  Swanson Gd,et al.  Triggering of sudden death from cardiac causes by vigorous exertion. , 2001 .

[41]  P. Poole‐Wilson,et al.  Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. , 2000, Circulation.

[42]  H P Schultheiss,et al.  Diurnal, weekly and seasonal variation of sudden death. Population-based analysis of 24,061 consecutive cases. , 2000, European heart journal.

[43]  T. Fahey,et al.  Estimation of cardiovascular risk in hypertensive patients in primary care. , 2000, The British journal of general practice : the journal of the Royal College of General Practitioners.

[44]  A. Katz,et al.  Seasonal variation in sudden death in the Negev desert region of Israel. , 2000, The Israel Medical Association journal : IMAJ.

[45]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[46]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[47]  D. Siscovick,et al.  Physical exertion as a trigger of myocardial infarction and sudden cardiac death. , 1996, Cardiology clinics.

[48]  J. Oss,et al.  IMPROVED SURVIVAL WITH AN IMPLANTED DEFIBRILLATOR IN PATIENTS WITH CORONARY DISEASE AT HIGH RISK FOR VENTRICULAR ARRHYTHMIA , 1996 .

[49]  M. Abrahamowicz,et al.  Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study , 1995, BMJ.

[50]  J. Jalife,et al.  Cardiac Electrophysiology: From Cell to Bedside , 1990 .

[51]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .